Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
epublish
Résumé
Use of doravirine (DOR), a new nonnucleoside reverse-transcriptase inhibitors recently approved for HIV treatment, is still unclear in clinical practice and real-life data are scarce. We retrospectively investigated the rationale for switching people with HIV to DOR-containing/-based regimens in a real-life cohort. Among 132 patients (68.9% males, median age 56 years), the main reasons to start DOR were prevention of toxicities (39.4%) and dyslipidemia (18.2%). DOR was combined with integrase inhibitors in 40.9% cases, and in 25.7% of patients, DOR was prescribed without availability of a genotypic resistance test. Twenty-four weeks after the switch to DOR-containing/-based regimens, no significant changes in CD4+ T-cell count, CD4/CD8 ratio, detectable HIV-RNA, serum creatinine levels, and body weight were detected. By contrast, a significant reduction in lipids (both cholesterol and triglycerides) was observed in 52 patients for whom a follow-up assessment was available (P = .008 and .01, respectively). Our data confirmed that switching to DOR-containing/-based regimens may have a favorable impact on lipid profile and a neutral impact on weight gain. However, more data are needed to support its use in patients who do not have a genotypic test available or have an extensive nonnucleoside reverse-transcriptase inhibitors-associated resistance, as well as its use in a dual regimen, especially in combination with second-generation integrase inhibitors.
Identifiants
pubmed: 35905209
doi: 10.1097/MD.0000000000029855
pii: 00005792-202207290-00012
pmc: PMC9333545
doi:
Substances chimiques
Anti-HIV Agents
0
Integrase Inhibitors
0
Pyridones
0
Reverse Transcriptase Inhibitors
0
Triazoles
0
doravirine
913P6LK81M
DNA-Directed RNA Polymerases
EC 2.7.7.6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29855Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
F.C. is principal investigator (honorary) in clinical studies supported by Gilead, ViiV Healthcare, Alfa Sigma, Medimmune s.r.l., Eiger Biopharmaceutical, Theravance Biopharma, Antibiotics, and received research grants from from Gilead, and ViiV Healthcare. M.F. received speakers’ honoraria, support for travel to meetings and/or fees for attending advisory boards from Bristol-Myers Squibb (BMS), Gilead, Janssen-Cilag, Merck Sharp and Dohme (MSD), ViiV Healthcare. A.M.C. received speakers’ honoraria, support for travel to meetings and/or fees for attending advisory boards from Gilead, Janssen-Cilag, and Merck Sharp and Dohme (MSD). E.Q.-R. received research grants from Gilead, Janssen-Cilag, Merck Sharp and Dohme (MSD), ViiV Healthcare. The other authors have no funding and conflicts of interest to disclose.
Références
Blevins SR, Hester EK, Chastain DB, et al. Doravirine: a return of the NNRTI class? Ann Pharmacother. 2020;54:64–74.
EACS guidelines 2021. 2020. Available at: https://www.eacsociety.org/guidelines/eacs-guidelines/ . [access date March 2, 2022].
Soulie C, Santoro MM, Charpentier C, et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J Antimicrob Chemother. 2019;74:614–7.
Stockdale AJ, Khoo S. Doravirine: its role in HIV treatment. Curr Opin HIV AIDS. 2022;17:4–14.
Wang X, Milinkovic A, Pereira B, et al. Pharmacokinetics of once-daily doravirine over 72 h following drug cessation. J Antimicrob Chemother. 2020;75:1658–60.
Molina JM, Squires K, Sax PE, et al. DRIVE-FORWARD trial group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7:e16–26.
Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) versus Efavirenz/Emtricitabine/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2021;73:33–42.
Kumar P, Johnson M, Molina JM, et al.; DRIVE-SHIFT Study Group. Brief report: switching to DOR/3TC/TDF Maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2021;87:801–5.
Sung M, Gordon K, Edelman EJ, et al. Polypharmacy and frailty among persons with HIV. AIDS Care. 2021;33:1492–9.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15:126–33.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines . [access date March 2, 2022].
Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a phase IIb trial. Antivir Ther. 2019;24:425–35.
Nelson M, Winston A, Hill A, et al. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021;35:759–67.
Fulco PP, Herity LB. Doravirine use in treatment-experienced hiv-positive patients. Ann Pharmacother. 2021;55:127–30.
Mazzitelli M, Sasset L, Leoni D, et al. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: a retrospective analysis. Medicine (Baltim). 2021;100:e28488.
Ciccullo A, D’Angelillo A, Iannone V, et al. Real-life safety of doravirine in treatment-experienced, virologically suppressed PLWHIV. J Acquir Immune Defic Syndr. 2021;88:e5–6.
AIFA. Linee guida studi osservazionali. 2021. Available at: https://www.aifa.gov.it/-/linee-guida-studi-osservazionali . [access date March 2, 2022].
HIV drug resistance database. Stanford University [database online]. 2008. Available at: https://hivdb.stanford.edu/ . [access date March 2, 2022].
Pelchen-Matthews A, Borges AH, Reekie J, et al. Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European Cohort. J Acquir Immune Defic Syndr. 2021;87:806–17.
NNRTI Resistance Notes on HIV drug resistance database. Stanford University [database online]. 2022. Available at: https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/ . [access date March 2, 2022].
Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27:111–21.
Sterrantino G, Borghi V, Callegaro AP, et al. Prevalence of predicted resistance to doravirine in HIV-1 positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019;53:515–9.
Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35:91–9.